Reply to Gohar on ‘Lungs, methotrexate and psoriasis’, a comment on ‘Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis’

A. Affleck (Lead / Corresponding author), A. Goudie, R. Smith

    Research output: Contribution to journalLetter

    10 Downloads (Pure)

    Abstract

    There may be a group of patients with psoriasis who are at increased risk of developing interstitial lung disease and identifying these individuals is desirable. However, at the present time we do not believe that routine screening with chest CT scanning is indicated nor any proposed preventative medical treatments both of which may have side-effects. 

    Original languageEnglish
    Pages (from-to)595
    Number of pages1
    JournalClinical and Experimental Dermatology
    Volume44
    Issue number5
    Early online date25 Apr 2019
    DOIs
    Publication statusPublished - 1 Jul 2019

    Keywords

    • Humans
    • Idiopathic Pulmonary Fibrosis
    • Lung
    • Methotrexate
    • Psoriasis

    Fingerprint Dive into the research topics of 'Reply to Gohar on ‘Lungs, methotrexate and psoriasis’, a comment on ‘Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis’'. Together they form a unique fingerprint.

  • Cite this